SUMMARY Recent reports have shown that /3-adrenergic blockade may exacerbate variant angina. On theoretical grounds, ca-adrenergic blockade may be beneficial in these patients. To test this hypothesis, we assessed the efficacy of prazosin, an ca-adrenergic blocking agent, in six men, mean age 49 years, with variant angina. Prazosin, 14.0 ± 2.4 mg/day (mean SD) in three equal doses, was compared with placebo in a double-blind, randomized, double-crossover trial lasting 41/2 months: 2 weeks of open-label prazosin followed by four 1-month periods of blinded alternating therapy. No other vasoactive medications were administered during the study.
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Prazosin reduced sitting systolic arterial pressure from 145 18 to 127 16 mm Hg (p = 0.02), but exerted no effect on diastolic arterial pressure or heart rate. Prazosin did not change the weekly number of episodes of chest pain (2.5 2.3 with placebo vs 3.1 3.0 with prazosin, NS), nitroglycerin tablets used (3.9 3.7 with placebo vs 4.6 4.2 with prazosin, NS), or transient ST-segment deviations (by calibrated two-channel Holter monitoring for 24 hours/week throughout the study) (6.5 + 10.1 with placebo vs 11.8 17.4 with prazosin, NS). During prazosin therapy, three patients had orthostatic dizziness and one patient had headache. Thus, in a long-term, randomized, double-blind trial, prazosin exerted no obvious beneficial effect in patients with variant angina.
ALTHOUGH the cause of coronary arterial spasm is unknown, several studies over the past 10 years have suggested that episodes of spasm may be mediated by stimulation of the a-adrenergic receptors of large coronary arteries. Studies in experimental animals have shown that coronary blood flow can be influenced markedly by stimulation or blockade of these a-adrenergic receptors. ' Some reports have strongly suggested that in patients with variant angina, a-adrenergic stimulation can induce clinical episodes of spasm, whereas a-adrenergic blockade is effective in alleviating these episodes.7-10 However, these studies were relatively brief and were not randomized or doubleblind. Therefore, we designed a long-term, placebocontrolled, randomized, double-blind study to assess the efficacy of prazosin, an a-adrenergic blocking agent, in patients with variant angina. Values are mean ± SD.
min and did not change significantly in the sitting position (70 + 6 beats/min) (NS compared with both the supine position during prazosin therapy and the sitting position during placebo therapy). Prazosin's effects on supine and sitting arterial pressure and heart rate were similar during both months of therapy. During the first month of prazosin treatment, supine systolic pressure averaged 134 + 17 mm Hg, and sitting systolic pressure 126 + 17 mm Hg. During the second month, supine pressure was 136 ± 19 mm Hg and sitting pressure was 127 + 18 mm Hg (NS compared with the values during the first month of prazosin therapy). During the first month of prazosin therapy, supine diastolic arterial pressure was 84 ± 9 mm Hg and sitting pressure was 82 ± 7 mm Hg. During the second month, supine diastolic pressure was 86 ± 8 mm Hg and sitting pressure was 84 ± 9 mm Hg (NS compared with the values during the first month of prazosin treatment). Finally, during the initial month of prazosin therapy, the supine heart rate averaged 69 8 beats/min and the sitting heart rate 71 ± 5 beats/min. During the second month, the supine heart rate was 67 + 7 beats/min and the sitting heart rate was 69 ± 6 beats/min (NS compared with the values during the first month of prazosin administration). There was no evidence in any of the patients that prazosin's influence on systemic arterial pressure or heart rate decreased with time.
Discussion
Several studies have suggested that a-adrenergic stimulation may induce variant angina and that aadrenergic blockade may alleviate these episodes.7'-0 At the same time, ,B-adrenergic blockade, usually accomplished with propranolol, may exacerbate variant angina, presumably by allowing a-adrenergic stimulation of the large coronary arteries to occur unopposed."4 In patients with variant angina, Yasue et al. 7 showed that a-adrenergic stimulation (produced by epinephrine or methacholine, a parasympathomimetic agent that reflexly stimulates sympathetic activity) as well as ,3-adrenergic blockade (with propranolol) induced episodes of variant angina. Yasue et al.8 consistently provoked coronary arterial spasm with subcutaneous epinephrine in patients already receiving propranolol. Subsequently, some unblinded and relatively short-term studies have demonstrated that episodes of variant angina can be abolished with i.v. phentolamine or oral phenoxybenzamine, both aadrenergic blocking agents,9, 10 whereas others have failed to demonstrate this effect.'5 Thus, these preliminary reports suggested that a-adrenergic blockade may be effective in at least some patients with variant angina. The success of a blockade may offer insight into the pathophysiology of coronary arterial spasm.
The present study was performed to assess the efficacy of prazosin in patients with variant angina. Because many patients with variant angina have marked variability in disease activity,16 17 we assessed prazosin's efficacy in a 4½/2-month, placebo-controlled, randomized, double-blind study. Prazosin was administered in doses similar to those used in patients with systemic arterial hypertension'8' 19 and those with severe congestive heart failure.20-22 Although prazosin induced a significant fall in systemic arterial pressure, it exerted no effect on the frequency of chest pain, nitroglycerin usage or transient ST-segment deviations. There are two basic subtypes of a-adrenergic receptors. Postsynaptic a1 receptors mediate the contraction of vascular smooth muscle and presynaptic a2 receptors inhibit norepinephrine release at nerve terminals. Although the regulation of vascular tone in vivo appears to be mediated primarily by postsynaptic. a, receptors,23 it may also be influenced by postsynaptic a2 receptors, which have been identified in a number of vascular tissues in expenmental animals.2425 Because these postsynaptic a2 receptors may help to control vascular tone in human coronary artenes, their stimulation may induce coronary arterial spasm and their blockade may prevent it.29 Prazosin has marked selectivity for postsynaptic a1 receptors. In this respect, it differs from phentolamine and phenoxybenzamine, which block both a, and a2 receptors. Therefore, although the present study demonstrates that postsynaptic al-receptor blockade with prazosin is not effective in patients with variant angina, it does not exclude the possibility that coronary arterial spasm is mediated by postsynaptic a2 receptor stimulation.
